Israel’s Therapix Biosciences (reported here previously) is working with the University of Calgary to evaluate the pain relief effect of its THX-160 analgesic. In pre-clinical studies, THX-160 was in some instances even more effective than high-dose morphine.

http://therapix.investorroom.com/2020-12-02-Therapix-Biosciences-to-Collaborate-with-The-University-of-Calgary-to-Further-Examine-its-Proprietary-Drug-Candidate-THX-160-for-Pain

https://therapixbio.com/